New flu pill passes first safety hurdle in small human study

NCT ID NCT05202379

Completed Disease control Sponsor: Cocrystal Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new oral drug called CC-42344 in 80 healthy adults to see if it is safe and how the body processes it. The drug is designed to stop the influenza A virus from multiplying. The study did not treat actual flu patients, but the results will help decide whether to test it further in people with the flu.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CC-42344 (an oral capsule that aims to stop the flu virus from multiplying)
What this could lead to: If safe and effective in later trials, this drug could become a new treatment option for influenza A, helping reduce symptoms and shorten illness.
What could go wrong: This is a very early Phase 1 study focused on safety and dosing in healthy people, not on treating flu. Many drugs fail in later stages, and it may not prove effective against the virus.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

swine influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA A

Contacts and locations

Locations

Linear Clinical Research

Nedlands, Western Australia, 6009, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.